Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Net revenue		$ 472,959	$ 415,441	$ 919,712	$ 856,686
Operating expenses:
Practice salaries and benefits		317,035	282,985	636,047	599,264
Practice supplies and other operating expenses		24,182	20,173	46,394	44,015
General and administrative expenses		70,968	60,488	137,484	127,930
Gain on sale of building		(7,280)		(7,280)
Depreciation and amortization		8,106	6,751	16,137	13,554
Transformational and restructuring related expenses		9,932	10,479	14,810	26,555
Total operating expenses		422,943	380,876	843,592	811,318
Income from operations		50,016	34,565	76,120	45,368
Investment and other income		4,176	3,576	10,143	2,530
Interest expense		(16,879)	(28,265)	(34,524)	(55,930)
Loss on early extinguishment of debt				(14,532)
Equity in earnings of unconsolidated affiliate		577	305	1,072	799
Total non-operating expenses		(12,126)	(24,384)	(37,841)	(52,601)
Income (loss) from continuing operations before income taxes		37,890	10,181	38,279	(7,233)
Income tax benefit (provision)		(7,363)	(3,097)	(2,408)	(4,182)
Income (loss) from continuing operations		30,527	7,084	35,871	(11,415)
Income (loss) from discontinued operations, net of tax		4,478	(679,520)	16,768	(679,733)
Net income (loss)		35,005	(672,436)	52,639	(691,148)
Net loss attributable to noncontrolling interest		6		14
Net income (loss) attributable to Mednax, Inc.		$ 35,011	$ (672,436)	$ 52,653	$ (691,148)
Income (loss) from continuing operations:
Basic		$ 0.36	$ 0.08	$ 0.42	$ (0.14)
Diluted		0.36	0.08	0.42	(0.14)
Income from discontinued operations:
Basic		0.05	(8.14)	0.20	(8.18)
Diluted		0.05	(8.11)	0.19	(8.18)
Net income (loss) attributable to Mednax, Inc.:
Basic		0.41	(8.06)	0.62	(8.32)
Diluted		$ 0.41	$ (8.03)	$ 0.61	$ (8.32)
Weighted average common shares:
Basic		84,912	83,490	84,660	83,061
Diluted	[1]	85,933	83,744	85,653	83,061

[1] Due to a loss from continuing operations for the six months ended June 30, 2020, no incremental shares are included because the effect would be antidilutive.